Get the Stockscreener App
53.93
4.67%
-2.64
Boston Scientific Corp stock is traded at $53.93, with a volume of 20.83M.
It is down -4.67% in the last 24 hours and down -13.79% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$56.57
Open:
$56.33
24h Volume:
20.83M
Relative Volume:
1.17
Market Cap:
$80.16B
Revenue:
$20.62B
Net Income/Loss:
$3.56B
P/E Ratio:
22.62
EPS:
2.3847
Net Cash Flow:
$3.48B
1W Performance:
-4.55%
1M Performance:
-13.79%
6M Performance:
-46.08%
1Y Performance:
-47.79%
1-Day Range:
$53.63
$56.62
1-Week Range:
$53.63
$58.18
52-Week Range:
$53.63
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
53.93 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
ABT
Abbott Laboratories
|
84.32 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
285.47 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
76.15 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
EW
Edwards Lifesciences Corp
|
79.96 | 46.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific Corp. stock (US10117L1017): Shares hit 52-week low after earnings beat and guidanc - AD HOC NEWS
Boston Scientific Corp (BSX) Stock Down 4.7% -- Now Undervalued? GF Score: 84/100 - GuruFocus
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
Endeavor plans to redevelop 24-acre Boston Scientific campus in Minnetonka - The Business Journals
Boston Scientific’s pacemaker recall is most serious type: FDA - Modern Healthcare News
Fund Update: 191,081 BOSTON SCIENTIFIC (BSX) shares added to Glenview Trust Co portfolio - Quiver Quantitative
Boston Scientific principal’s advice: ‘Build the doors you want to walk through’ - The Business Journals
Boston Scientific Corp. Stock (US10117L1017): Hits 52-Week Low Amid Analyst Downgrades and Guidance - AD HOC NEWS
Boston Scientific Announces Software Upgrade for Pacemakers Amid Recall - GuruFocus
US FDA issues recall of Boston Scientific heart devices - Reuters
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
Penumbra shareholders approve merger with Boston Scientific - Investing.com
Fund Update: 543,460 BOSTON SCIENTIFIC (BSX) shares added to Mawer Investment Management Ltd. portfolio - Quiver Quantitative
FMR LLC updates Boston Scientific holding (NYSE: BSX) — 75.8M shares - Stock Titan
Do Boston Scientific's (NYSE:BSX) Earnings Warrant Your Attention? - Yahoo Finance
BSX Technical Analysis | Trend, Signals & Chart Patterns | BOSTON SCIENTIFIC CORP (NYSE:BSX) - ChartMill
Boston Scientific Corporation Restated Certificate of Incorporation: Key Provisions, Director Rights, and Shareholder Protections - Minichart
Boston Scientific shareholders approve charter amendments and board elections By Investing.com - Investing.com Canada
Boston Scientific shareholders approve charter amendments and board elections - Investing.com
Boston Scientific (NYSE: BSX) investors approve charter changes and board slate - Stock Titan
Boston Scientific Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Boston Scientific stock hits 52-week low at 56.04 USD By Investing.com - Investing.com UK
Boston Scientific stock hits 52-week low at 56.04 USD - Investing.com
Boston Scientific (BSX) EVP manages tax on 1,802 RSU vesting - Stock Titan
Boston Scientific (NYSE: BSX) EVP exercises RSUs and withholds shares for taxes - Stock Titan
BSX Stock Quote Price and Forecast - CNN
BSX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - Business Wire
Penumbra earnings in focus as Boston Scientific deal looms - Investing.com
BSX DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class ActionBSX - TMX Newsfile
Piper Sandler reiterates Boston Scientific stock rating on survey - Investing.com
Boston Scientific maps out May conference appearance, July 29 Q2 call - Stock Titan
Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results - Barchart.com
BSX Stock Price, Quote & Chart | BOSTON SCIENTIFIC CORP (NYSE:BSX) - ChartMill
Penobscot Investment Management Company, Inc.'s Boston Scientific Corp(BSX) Holding History - GuruFocus
BSX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class ActionBSX - Scott Coop
Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
BSX Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
Boston Scientific Corporation (NYSE:BSX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Boston Scientific Corp. Opens with 4.84% Gain, Outperforming S&P 500's 1.05% Increase - Markets Mojo
BSX Deadline: BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit - ChartMill
Boston Scientific Corporation (BSX): Billionaire Tom Steyer Is Loading Up on This Stock - Insider Monkey
BSX 72 HOUR DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
Boston Scientific AGM: $20B 2025 Sales, Governance Votes Pass, Special Meeting Proposals Fail - Yahoo Finance
Boston Scientific Q1 2026 Financial Results: Earnings, Risk Factors, and Comprehensive Performance Overview - Minichart
Teza Capital Management LLC's Boston Scientific Corp(BSX) Holding History - GuruFocus
Boston Scientific Corp 1Q 2026: Revenue $5.2B, EPS $0.9— 10-Q Summary - TradingView
BSX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - ChartMill
Wall Street Analysts Think Boston Scientific (BSX) Is a Good Investment: Is It? - Yahoo Finance
Inside Boston Scientific's $15 billion offer for Alameda's largest employer - The Business Journals
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Oppenheimer Asset Management Inc. Sells 21,543 Shares of Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.32%
3.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):